{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:41:16Z","timestamp":1787622076679,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s13555-025-01451-w","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:33:35Z","timestamp":1751621615000},"page":"2439-2453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploring Vitiligo History and Mental Health Burden Among People Within EU5 Countries: Findings from the Global VALIANT Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-4589","authenticated-orcid":false,"given":"Khaled","family":"Ezzedine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-6430","authenticated-orcid":false,"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3137-5601","authenticated-orcid":false,"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6871-2333","authenticated-orcid":false,"given":"Kristen","family":"Bibeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessy","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4694-2795","authenticated-orcid":false,"given":"Haobo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-8195","authenticated-orcid":false,"given":"Nanja","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"issue":"1","key":"1451_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017;77(1):1\u201313.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1451_CR2","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau K, Pandya AG, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1451_CR3","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S2468-2667(24)00026-4","volume":"9","author":"J Akl","year":"2024","unstructured":"Akl J, Lee S, Ju HJ, et al. Estimating the burden of vitiligo: a systematic review and modelling study. Lancet Public Health. 2024;9(6):e386\u201396.","journal-title":"Lancet Public Health"},{"issue":"5","key":"1451_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/bjd\/ljad245","volume":"189","author":"IH Hamzavi","year":"2023","unstructured":"Hamzavi IH, Bibeau K, Grimes P, et al. Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study. Br J Dermatol. 2023;189(5):569\u201377.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1451_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"K Bibeau","year":"2023","unstructured":"Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 2023;159(10):1124\u20138.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1451_CR6","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1111\/bjd.15933","volume":"177","author":"B Morrison","year":"2017","unstructured":"Morrison B, Burden-Teh E, Batchelor JM, Mead E, Grindlay D, Ratib S. Quality of life in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2017;177(6):e338\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1451_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757\u201374.","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"1451_CR8","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/jdv.14739","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis. J Eur Acad Dermatol Venereol. 2018;32(8):1343\u201351.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1451_CR9","doi-asserted-by":"publisher","first-page":"6663646","DOI":"10.1155\/2021\/6663646","volume":"2021","author":"J Liu","year":"2021","unstructured":"Liu J, Tang R, Xiao Y, et al. Meta-analytic review of high anxiety comorbidity among patients with vitiligo. Biomed Res Int. 2021;2021:6663646.","journal-title":"Biomed Res Int."},{"issue":"3","key":"1451_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jaad.2021.02.083","volume":"86","author":"M Condamina","year":"2022","unstructured":"Condamina M, Shourick J, Seneschal J, et al. Factors associated with perceived stress in patients with vitiligo in the ComPaRe e-cohort. J Am Acad Dermatol. 2022;86(3):696\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1451_CR11","first-page":"255","volume":"95","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI, Silverberg NB. Vitiligo disease triggers: psychological stressors preceding the onset of disease. Cutis. 2015;95(5):255\u201362.","journal-title":"Cutis"},{"issue":"3","key":"1451_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaad.2016.09.034","volume":"76","author":"N van Geel","year":"2017","unstructured":"van Geel N, Lommerts JE, Bekkenk MW, et al. Development and validation of a patient-reported outcome measure in vitiligo: the Self Assessment Vitiligo Extent Score (SA-VES). J Am Acad Dermatol. 2017;76(3):464\u201371.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1451_CR13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaad.2019.02.008","volume":"81","author":"K Ezzedine","year":"2019","unstructured":"Ezzedine K, Ahmed M, Tovar-Garza A, et al. Cross-cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs). J Am Acad Dermatol. 2019;81(5):1107\u201314.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1451_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"1451_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjd.20596","volume":"186","author":"V Eleftheriadou","year":"2022","unstructured":"Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18\u201329.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1451_CR16","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/jdv.19451","volume":"37","author":"N van Geel","year":"2023","unstructured":"van Geel N, Speeckaert R, Ta\u00efeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023;37(11):2173\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1451_CR17","first-page":"YC01","volume":"8","author":"N Mishra","year":"2014","unstructured":"Mishra N, Rastogi MK, Gahalaut P, Agrawal S. Dermatology specific quality of life in vitiligo patients and its relation with various variables: a hospital based cross-sectional study. J Clin Diagn Res. 2014;8(6):YC01\u20133.","journal-title":"J Clin Diagn Res."},{"issue":"2","key":"1451_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/jdv.17742","volume":"36","author":"J Shourick","year":"2022","unstructured":"Shourick J, Seneschal J, Andreu N, et al. Vitiligo Treatment Impact score (VITs): development and validation of a vitiligo burden of treatment questionnaire using the ComPaRe Vitiligo e-cohort. J Eur Acad Dermatol Venereol. 2022;36(2):279\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1451_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00403-024-02872-x","volume":"316","author":"S Poondru","year":"2024","unstructured":"Poondru S, Yang LJ, Kundu RV. Use of complementary and alternative medicine in vitiligo: a cross-sectional survey. Arch Dermatol Res. 2024;316(5):126.","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"1451_CR20","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jdv.19450","volume":"37","author":"J Seneschal","year":"2023","unstructured":"Seneschal J, Speeckaert R, Taieb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force-part 2: specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023;37(11):2185\u201395.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1451_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamadermatol.2013.927","volume":"149","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013;149(2):159\u201364.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01451-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01451-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01451-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:39:06Z","timestamp":1757205546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01451-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1451"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01451-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Khaled Ezzedine is a consultant for AbbVie, Incyte, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio. John E. Harris has served as a consultant for AbbVie, Aclaris Therapeutics, BiologicsMD, EMD Serono, Genzyme\/Sanofi, Janssen, Pfizer, Rheos Medicines, Sun Pharmaceuticals, TeVido BioDevices, The Expert Institute, 3rd Rock Ventures, and Villaris Therapeutics; has served as an investigator for Aclaris Therapeutics, Celgene, Dermira, EMD Serono, Genzyme\/Sanofi, Incyte, LEO Pharma, Pfizer, Rheos Medicines, Stiefel\/GlaxoSmithKline, Sun Pharmaceuticals, TeVido BioDevices, and Villaris Therapeutics; holds equity in Aldena Therapeutics, NIRA Biosciences, Rheos Medicines, TeVido BioDevices, and Villaris Therapeutics; is a scientific founder of Aldena Therapeutics, NIRA Biosciences, and Villaris Therapeutics; and has patents pending for IL-15 blockade for treatment of vitiligo, JAK inhibition with light therapy for vitiligo, and CXCR3 antibody depletion for treatment of vitiligo. Iltefat H. Hamzavi has served as a consultant and investigator for AbbVie, Almirall, Avita, Boehringer Ingelheim, Galderma, Incyte, Janssen, Novartis, Pfizer, Sonoma, UCB, Union Therapeutics, and Vimela; immediate past president of the HS Foundation; and a board member of the Global Vitiligo Foundation. Kristen Bibeau was an employee and shareholder of Incyte at the time of this study. Jessy Gao and Haobo Ren are employees and shareholders of Incyte. Nanja van Geel is a consultant and\/or investigator for AbbVie, Bristol Myers Squibb, Idorsia Pharmaceuticals, Incyte, Merck\/MSD, Pfizer, and Sun Pharma; and is Chair of the Vitiligo Task Force for the European Academy of Dermatology and Venereology (EADV).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and in adherence to the study protocol and local regulatory requirements. All survey participants provided informed consent at screening and could withdraw consent at any time. The study protocol received an exemption from the Western Institutional Review Board, given the survey procedures and use of deidentified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}